Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
AI Summary: The FDA has rejected Disc Medicine’s application for its rare-disease candidate even after granting an accelerated review pathway, concluding the submitted evidence did not demonstrate sufficient benefit. The setback stalls a high-profile regulatory push and requires the company to collect more robust clinical data before re‑seeking approval.
Predicting onset of symptomatic Alzheimerʼs disease with plasma p-tau217 clocks
Kellen K. Petersen / nature - Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04206-yPlasma p-tau217 tests used to develop clocks that predict when cognitively unimpaired individuals would develop symptoms of Alzheimerʼs disease.
AI Summary: A Nature Medicine study presents plasma p‑tau217 “clocks” that estimate when symptomatic Alzheimer’s disease is likely to begin, offering a blood-based forecast years before cognitive decline appears. The test could reshape trial enrollment, early intervention timing and patient counseling—validation and access hurdles remain, but at least worried boomers get a calendar to dread.
FDA formalizes one pivotal trial policy via NEJM perspective
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
AI Summary: The FDA has moved to make a single pivotal trial the new default for drug approvals, abandoning the long-standing two-study standard to speed access and ease OTC transitions. The policy, outlined by agency leaders and discussed in a NEJM perspective, raises questions about evidence thresholds and downstream safety monitoring. Welcome to faster approvals — now let's hope that lone study behaves.
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
AI Summary: After renewed discussions with the company, the FDA reversed its earlier stance and agreed to accept Moderna’s amended application for an mRNA seasonal influenza vaccine. Regulators will now evaluate the submitted safety and efficacy data to determine whether the shot meets approval standards — a regulatory about-face that will keep flu-watchers and investors awake.
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test
Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…
AI Summary: Ocular Therapeutix’s investigational drug Axpaxli met its primary endpoint in a pivotal Phase 3 trial, showing superiority to Regeneron’s Eylea for wet age‑related macular degeneration. The company plans an FDA submission, positioning Axpaxli as a potential new first‑line therapy if regulators agree — a welcome development for patients tired of frequent injections.
Can medical AI lie? Large study maps how LLMs handle health misinformation
medicalxpress - Medical artificial intelligence (AI) is often described as a way to make patient care safer by helping clinicians manage information. A new study by the Icahn School of Medicine at Mount Sinai and collaborators confronts a critical vulnerability: when a m…
AI Summary: A broad analysis — including Mount Sinai research — shows large language models and medical AI systems can propagate false or misleading health claims when presented in realistic clinical language. Findings expose safety gaps, underline risks of unchecked deployment, and call for tighter guardrails, validation and clinician oversight before clinical use.
Lilly appeals retatrutide classification ruling in case that could impact compounders
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
AI Summary: Eli Lilly is contesting a regulatory classification decision for its next‑generation obesity shot while simultaneously stockpiling doses ahead of potential U.S. approval. The dispute has broader implications for compounding pharmacies and has coincided with lawsuits accusing telehealth vendors and compounders of selling unapproved oral GLP‑1 alternatives — a messy intersection of commerce, regulation and patient safety.
Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…
AI Summary: In a controversial translational study investigators ran blood between genetically modified pig livers and brain‑dead human decedents using an extracorporeal cross‑circulation system to assess organ viability and function. The work explores a potential bridge to expand transplantable organs, laying technical groundwork while prompting ethical and regulatory questions about next steps.
New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer
discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.
AI Summary: The FDA approved a wearable device that delivers alternating electric fields to disrupt pancreatic tumor growth, letting patients remain ambulatory while receiving treatment. Clinicians hail the noninvasive approach as a new adjunct to standard care, aiming to slow progression in a cancer that’s notoriously hard to treat — and yes, it literally plugs into hope.
FDA clears 1st blood test for Alzheimer’s in primary care
Ella Jeffries / beckershospitalreview - The first FDA-cleared blood test to assess Alzheimer’s disease in primary care is now available for patients age 55 and older with symptoms of cognitive decline. The test aims to help clinicians rule out Alzheimer’s by identifying individuals unlikely to …
AI Summary: Regulators cleared the first blood test for Alzheimer’s for primary‑care use while researchers published capillary sampling methods and analyses showing blood biomarkers’ promise for dementia diagnosis. Together these developments push biomarker testing out of specialty clinics and toward routine care — promising earlier detection, though concerns about population diversity, accuracy thresholds and rollout logistics remain.
FDA to reassess the safety of BHA, a preservative used in popular snack foods
go - Federal health officials will reassess the safety of a chemical called BHA used in foods including potato chips, cereals, frozen meals and meat products
AI Summary: U.S. regulators have moved to reevaluate butylated hydroxyanisole (BHA), a common food preservative, ordering a fresh safety review after mounting evidence and public concern. The reassessment could lead to updated guidance or restrictions — which will delight activists and mildly inconvenience snack manufacturers.
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing
Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…
AI Summary: BridgeBio reported statistically significant Phase 3 results for infigratinib in achondroplasia, showing improved growth rates and body composition, moving the program toward an FDA filing. The readout strengthens BridgeBio’s rare-disease momentum and sets the stage for regulatory discussions and potential market entry.
FDA refuses to review Moderna flu vaccine
Ella Jeffries / beckershospitalreview - Moderna has received a refusal-to-file letter from the FDA’s Center for Biologics Evaluation and Research for its biologics license application for mRNA-1010, its investigational seasonal influenza vaccine. The letter, signed by Vinayak Prasad, MD, chief …
AI Summary: Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making.
AstraZeneca gets CRL for prefilled pen version of lupus drug Saphnelo
Anna Brown / endpoints - The FDA has handed AstraZeneca a complete response letter for the subcutaneous prefilled, self-injectable pen of Saphnelo for systemic lupus erythematosus (SLE), a month after the asset gained approval in Europe ...
AI Summary: AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market.
Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade
Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…
AI Summary: Summit Therapeutics announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for Ivonescimab—intended for patients with EGFR‑mutated non‑small cell lung cancer who have progressed after TKI therapy. The regulatory nod signals a promising step forward in targeted lung cancer treatment.
FDA lifts hold on one of two Phase 3 gene editing studies by Intellia
Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia
AI Summary: U.S. regulators have just cleared Intellia Therapeutics’ Phase 3 study of a gene‐editing therapy intended to treat a genetic nerve disorder, effectively rescinding a clinical hold. This development opens the door to renewed patient enrolment and further evaluation of the treatment’s safety and effectiveness.
Oregon baby is still battling infant botulism after ByHeart formula exposure
go - A Portland, Oregon, baby got sick with infant botulism after drinking contaminated ByHeart formula donated through a program that helps poor and homeless families
AI Summary: Two reports describe how a Portland baby continues to struggle with severe infant botulism after ingesting contaminated ByHeart formula distributed via a charity, raising concerns about quality control and the safety of aid programs.
F.D.A. Decisions on Abortion Pill Were Based on Science, New Analysis Finds
Pam Belluck / nytimes - A study of more than 5,000 pages of agency documents on mifepristone over 12 years found that agency leaders almost always followed the evidence-based recommendations of scientists.
AI Summary: New in‑depth analyses of internal FDA documents reveal that regulatory decisions on the abortion pill mifepristone were firmly based on thorough evidence rather than political pressure, dispelling common misconceptions about politicized review processes.
FDA rejects cancer therapy for rare post-transplant disease
Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …
AI Summary: The FDA has again rejected Atara’s cell therapy aimed at treating rare post‐transplant complications linked to Epstein–Barr virus. Despite high hopes for this innovative approach, regulatory concerns remain over its safety and efficacy—clearly a “repeat performance” in the world of breakthrough therapies.
FDA moves to remove suicide warnings from GLP-1 weight loss drugs
medicalxpress - Federal health regulators say popular weight loss drugs like Wegovy and Zepbound do not increase the risk of suicidal thoughts, and they have asked drugmakers to remove those warnings from medication labels.
AI Summary: In a surprising twist, the FDA has decided that the long‐rumored risk of suicidal ideation on popular GLP‑1 weight‐loss drugs may have been overblown. Regulators have now asked drugmakers – including Lilly and Novo Nordisk – to scrub these warnings from product labels, a move that is sure to spark both relief and raised eyebrows among critics.